Tumor-derived lactic acid modulates dendritic cell activation and antigen expression - PubMed

Affiliations

• PMID: 16278308
• DOI: 10.1182/blood-2005-05-1795

Free article

Tumor-derived lactic acid modulates dendritic cell activation and antigen expression

Eva Gottfried et al. Blood. 2006.

Free article

Abstract

The tumor milieu can influence dendritic cell (DC) differentiation. We analyzed DC differentiation in a 3-dimensional tumor model and propose a new mechanism of DC modulation by the tumor environment. Monocytes were cultured in the presence of IL-4 and GM-CSF within multicellular tumor spheroids (MCTSs) generated from different tumor cell lines. Monocytes invaded the MCTSs and differentiated into tumor-associated dendritic cells (TADCs). The antigen expression was altered on TADCs independent of the culture conditions (immature/mature DCs, Langerhans cells) and IL-12 secretion was reduced. Supernatants of MCTSs could partially transfer the suppressive effect. Conditioned media from urothelial carcinoma cell lines contained high levels of M-CSF and IL-6, both cytokines known to modulate DC differentiation. In contrast, melanoma and prostate carcinoma MCTS cocultures produced little M-CSF and IL-6, but high levels of lactic acid. Indeed, addition of lactic acid during DC differentiation in vitro induced a phenotype comparable with TADCs generated within melanoma and prostate carcinoma MCTSs. Blocking of lactic acid production in melanoma MCTS cocultures reverted the TADC phenotype to normal. We therefore conclude that tumor-derived lactic acid is an important factor modulating the DC phenotype in the tumor environment, which may critically contribute to tumor escape mechanisms.

Similar articles

• Induction of suppressive phenotype in monocyte-derived dendritic cells by leukemic cell products and IL-1β.

  Motta JM, Sperandio A, Castelo-Branco MT, Rumjanek VM. Motta JM, et al. Hum Immunol. 2014 Jul;75(7):641-9. doi: 10.1016/j.humimm.2014.04.013. Epub 2014 Apr 24. Hum Immunol. 2014. PMID: 24768898

• Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation.

  Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Bharadwaj U, et al. Cancer Res. 2007 Jun 1;67(11):5479-88. doi: 10.1158/0008-5472.CAN-06-3963. Cancer Res. 2007. PMID: 17545630

• Mixed Langerhans cell and interstitial/dermal dendritic cell subsets emanating from monocytes in Th2-mediated inflammatory conditions respond differently to proinflammatory stimuli.

  Bechetoille N, André V, Valladeau J, Perrier E, Dezutter-Dambuyant C. Bechetoille N, et al. J Leukoc Biol. 2006 Jul;80(1):45-58. doi: 10.1189/jlb.0205109. Epub 2006 Apr 13. J Leukoc Biol. 2006. PMID: 16614258

• Brave little world: spheroids as an in vitro model to study tumor-immune-cell interactions.

  Gottfried E, Kunz-Schughart LA, Andreesen R, Kreutz M. Gottfried E, et al. Cell Cycle. 2006 Apr;5(7):691-5. doi: 10.4161/cc.5.7.2624. Epub 2006 Apr 1. Cell Cycle. 2006. PMID: 16582627 Review.

• Cytokines in the generation and maturation of dendritic cells: recent advances.

  Zou GM, Tam YK. Zou GM, et al. Eur Cytokine Netw. 2002 Apr-Jun;13(2):186-99. Eur Cytokine Netw. 2002. PMID: 12101074 Review.

Cited by

• Impact of NSCLC metabolic remodeling on immunotherapy effectiveness.

  Lv L, Huang RH, Li J, Xu J, Gao W. Lv L, et al. Biomark Res. 2022 Aug 29;10(1):66. doi: 10.1186/s40364-022-00412-1. Biomark Res. 2022. PMID: 36038935 Free PMC article. Review.

• Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming.

  Selleri S, Bifsha P, Civini S, Pacelli C, Dieng MM, Lemieux W, Jin P, Bazin R, Patey N, Marincola FM, Moldovan F, Zaouter C, Trudeau LE, Benabdhalla B, Louis I, Beauséjour C, Stroncek D, Le Deist F, Haddad E. Selleri S, et al. Oncotarget. 2016 May 24;7(21):30193-210. doi: 10.18632/oncotarget.8623. Oncotarget. 2016. PMID: 27070086 Free PMC article.

• Targeting cancer cell metabolism in pancreatic adenocarcinoma.

  Cohen R, Neuzillet C, Tijeras-Raballand A, Faivre S, de Gramont A, Raymond E. Cohen R, et al. Oncotarget. 2015 Jul 10;6(19):16832-47. doi: 10.18632/oncotarget.4160. Oncotarget. 2015. PMID: 26164081 Free PMC article. Review.

• Immunometabolism of dendritic cells in health and disease.

  Guo C, Chi H. Guo C, et al. Adv Immunol. 2023;160:83-116. doi: 10.1016/bs.ai.2023.10.002. Epub 2023 Oct 25. Adv Immunol. 2023. PMID: 38042587 Free PMC article. Review.

• Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

  Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Smith M, et al. Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018. Oncoimmunology. 2018. PMID: 30524908 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program